Golimumab · Immgolis, Simponi

What is Golimumab?

Golimumab is a human monoclonal antibody that binds both soluble and transmembrane forms of TNFα, preventing TNFα from binding its receptors and thereby inhibiting its inflammatory activity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Immgolis, Simponi, Simponi Aria, CNTO-148

Drug type

Monoclonal antibody

Targets

tumor necrosis factor alpha (TNF)

Mechanism

Antagonist of tumor necrosis factor alpha (TNF)

Pathways

TNFα signaling, leukocyte adhesion molecule expression (E-selectin, ICAM-1, VCAM-1), proinflammatory cytokine secretion (IL-6, IL-8, G-CSF, GM-CSF)

Therapy area

Immunology, Musculoskeletal

Developer

Centocor Ortho Biotech Inc

In trials of

ALVO

FDA status

Approved as Immgolis, Simponi, Simponi Aria (April 24, 2009), BLA125289 · FDA label

UNII

91X1KLU43E

✅ FDA-approved uses

• Rheumatoid Arthritis (Simponi Aria)
• Psoriatic Arthritis (Simponi Aria)
• Ankylosing Spondylitis (Simponi Aria)
• Polyarticular Juvenile Idiopathic Arthritis (Simponi Aria)

From the indications section of the FDA label (version of Sep 9, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

Other drugs acting on TNF

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Simponi Aria (2025-09-09), indications
• ClinicalTrials.gov NCT05842213

Updated Oct 11, 2026.